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Abstract
Introduction Human breast tumors are heterogeneous and
consist of phenotypically diverse cells. Breast cancer cells with
a CD44+/CD24-  phenotype have been suggested to have
tumor-initiating properties with stem cell-like and invasive
features, although it is unclear whether their presence within a
tumor has clinical implications. There is also a large
heterogeneity between tumors, illustrated by reproducible
stratification into various subtypes based on gene expression
profiles or histopathological features. We have explored the
prevalence of cells with different CD44/CD24 phenotypes
within breast cancer subtypes.
Methods Double-staining immunohistochemistry was used to
quantify CD44 and CD24 expression in 240 human breast
tumors for which information on other tumor markers and clinical
characteristics was available. Gene expression data were also
accessible for a cohort of the material.
Results A considerable heterogeneity in CD44 and CD24
expression was seen both between and within tumors. A
complete lack of both proteins was evident in 35% of the
tumors, while 13% contained cells of more than one of the
CD44+/CD24-, CD44-/CD24+ and CD44+/CD24+ phenotypes.
CD44+/CD24-  cells were detected in 31% of the tumors,
ranging in proportion from only a few to close to 100% of tumor
cells. The CD44+/CD24- phenotype was most common in the
basal-like subgroup – characterized as negative for the estrogen
and progesterone receptors as well as for HER2, and as positive
for cytokeratin 5/14 and/or epidermal growth factor receptor,
and particularly common in BRCA1 hereditary tumors, of which
94% contained CD44+/CD24-  cells. The CD44+/CD24-
phenotype was surprisingly scarce in HER2+ tumors, which had
a predominantly CD24+  status. A CD44+/CD24-  gene
expression signature was generated, which included CD44 and
α6-integrin (CD49f) among the top-ranked overexpressed
genes.
Conclusion We demonstrate an association between basal-like
and particularly BRCA1 hereditary breast cancer and the
presence of CD44+/CD24- cells. Not all basal-like tumors and
very few HER2+ tumors, however, contain CD44+/CD24- cells,
emphasizing that a putative tumorigenic ability may not be
confined to cells of this phenotype and that other breast cancer
stem cell markers remain to be identified.
Introduction
Human breast cancer is a truly complex disease with a large
inter-tumoral and intra-tumoral heterogeneity resulting in highly
variable clinical behavior and response to therapy. The mainte-
nance of the heterogeneity of cells within a tumor is not fully
understood. Possibly, every cell within a tumor may have a
capacity to proliferate and form new tumors, although the like-
lihood for each cell is very low. Alternatively, only a small sub-
set of cells with distinct characteristics has the capacity to
maintain tumor growth.
CK = cytokeratin; DAB = diaminobenzidene; EGFR = epidermal growth factor receptor; ER = estrogen receptor; PgR = progesterone receptor; SR 
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A population of CD44+/CD24-/low  cells has been demon-
strated to have tumor-initiating properties in breast cancer [1].
This tumorigenic phenotype has been associated with stem
cell-like characteristics [2], with enhanced invasive properties
[3], with radiation resistance [4] and with distinct genetic pro-
files suggesting correlation to adverse prognosis [5]. The
prevalence of CD44+/CD24-/low cells within breast tumors,
however, has not been significantly associated with clinical
characteristics – although tumors with a higher fraction of
CD44+/CD24- cells were more commonly found in patients
diagnosed with distant metastases [6].
Breast cancers have been classified based on their gene
expression profiles into luminal A and B, basal-like, HER2+
and normal breast-like subtypes [7-10]. These subtypes have
been associated with diverse tumor characteristics and clini-
cal outcome. The luminal subtypes are associated with expres-
sion of the estrogen receptor (ER), while basal-like and
normal-like tumors are essentially all ER-negative, as are the
majority of HER2+ tumors. Multiple studies have demon-
strated basal-like tumors to have a particularly poor prognosis
[8,9,11], although it is unclear whether basal-like tumors have
a significantly worse clinical outcome than other ER-negative
tumors [12]. Immunohistochemical features have been used to
characterize basal-like tumors as typically negative for ER, for
the progesterone receptor (PgR) and for HER2 but positive for
basal cytokeratins (CK5/6/14/17), for epidermal growth factor
receptor (EGFR) and/or for c-kit [13-15].
A correlation of the CD44+/CD24-/low phenotype to specific
breast cancer subtypes has not yet been reported in human
breast tumors. In the present article we have determined the
expression of CD44 and CD24 in human breast tumors using
double-staining immunohistochemistry and have correlated
the presence of CD44+/CD24- cells to subgroups of breast
cancer, classified using the expression of ER, PgR, HER2,
CK5/14 and EGFR, as well as by mRNA expression profiles.
We demonstrate an association of the CD44+/CD24- pheno-
type to basal-like and BRCA1 hereditary breast cancer.
Materials and methods
Patients
We studied 240 tumors from a cohort of 445 patients surgi-
cally treated for stage II breast cancer (age 31 to 81 years),
diagnosed in the South Swedish Health Care Region between
1985 and 1994 and originally participating in two randomized
clinical trials [16,17]. All patients received 2 years of adjuvant
tamoxifen treatment, without stratification according to ER sta-
tus. The median follow-up time for patients alive and free from
metastasis at the last follow-up visit was 5.3 years. The current
study was approved by the Lund University Medical Ethics
Committee.
Tumor characteristics
Fresh-frozen tumor tissue was used for routine determination
of cytosolic ER and PgR, as well as the S-phase fraction, using
an enzyme immunoassay and DNA flow cytometry, respec-
tively, as described earlier [18,19]. Cores of 0.6 mm diameter
formalin-fixed, paraffin-embedded tumor tissue were used to
generate tissue microarrays (TMAs) for the 445 cases. Three
cores from every individual tumor were arrayed. These TMAs
have been used for immunohistochemical staining of CK5,
CK14, EGFR and cytokeratin clone AE1/AE3 as described
previously [12,20]. A pathologist re-evaluated the histological
type on whole formalin-fixed paraffin-embedded sections [21].
BRCA1 tissue microarray
An additional TMA consisting of tumors from 23 BRCA1
germline mutation carriers, diagnosed in Sweden between
1980 and 2001, was used for evaluation purpose. This TMA
was generated as described above, including two or three
cores from each tumor.
Immunohistochemical staining
Sections (4 μm) of the TMA blocks were mounted on Dako
REAL™ Capillary Gap Microscope Slides (DAKO, Glostrup,
Denmark), were deparaffinized in xylene and were rehydrated
in ethanol. Antigen retrieval was achieved either by placing
slides in Tris-ethylenediamine tetraacetic acid buffer (pH 9.0)
at 125°C in a 2100 Retriever (PickCell Laboratories, Amster-
dam, the Netherlands) for 5 minutes (CD44/CD24), or by
microwaving the slides in Tris-ethylenediamine tetraacetic acid
buffer (pH 9.0) for 7 minutes at 800 W followed by 15 minutes
at 350 W (HER2).
Double-immunostaining with antibodies for detection of CD44
and CD24 was performed by an Autostainer (DAKO) using
EnVision G|2 Doublestain System Rabbit/Mouse (DAB+/Per-
manent Red) (DAKO) according to the manufacturer's instruc-
tions. Antibodies for the detection of CD44 (Clone 156-3C11,
1:800) and CD24 (Clone SN3b, 1:400) were purchased from
Neomarkers (Fremont, CA, USA). CD44 was detected with
Permanent Red and CD24 was detected using diaminobenzi-
dene (DAB).
HER2 was detected with a rabbit polyclonal primary antibody
(A0485, 1:1,000; DAKO) followed by EnVision™ on a Tech-
Mate™ (DAKO). All slides were counterstained with hematox-
ylin for the identification of nuclei.
Immunohistochemical evaluation
The scoring was performed twice by one person in a blinded
fashion. All unclear cases were discussed with a pathologist.
In case of discrepant staining between the three cores from
the same patient, an average was used.
HER2 scoring was carried out according to the standard pro-
cedure (DAKO): 0, < 10% of the tumor cells showedAvailable online http://breast-cancer-research.com/content/10/3/R53
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membranous staining; 1, > 10% of the tumor cells were posi-
tive but not circumferential; 2, weak staining around the whole
membrane in > 10% of the tumor cells; and 3, strong staining
around the membrane in > 10% of the tumor cells. CD44
staining was detected mainly in the membrane and the scoring
was as follows: 0, 0% positive tumor cells; 1, 1% to 10% pos-
itive cells; 2, 11% to 50% positive cells; 3, 51% to 75% pos-
itive cells; and 4, 76% to 100% positive cells. CD24 staining
was detected mainly in the cytoplasm and the scoring was
performed as described for CD44.
The proportion of CD44+/CD24- tumor cells was determined
as the percentage of cells positive for Permanent Red staining
but negative for DAB staining. The frequencies of CD44-/
CD24+ cells and of CD44+/CD24+ cells were determined in a
similar fashion.
Statistical analysis
Associations between the presence of CD44, CD24 or differ-
ent CD44/CD24 phenotypes and clinical variables as well as
breast cancer subgroups were assessed by Fisher's exact
test, except for age where the Mann-Whitney U test was used.
The Kaplan-Meier method was used to estimate distant dis-
ease-free survival, and the log-rank test to compare survival
between two strata. All tests were two-sided and P < 0.05
was considered significant. Statistical analyses were carried
out using Stata 10.0 software (Stata Corporation, College
Station, TX, USA).
Microarrays and data analysis
For 168 of the 445 tumors in our cohort, mRNA expression
analysis has previously been performed using cDNA microar-
rays with 27,648 reporters [22,23]. The microarray data for
these 168 tumors are available through the Gene Expression
Omnibus database (accession numbers GSE6577 and
GSE5325). Data pre-processing and filtering for the selected
168 tumors were performed using the BioArray Software Envi-
ronment [24] as previously described [23], leaving 15,040
reporters that were used for all subsequent analyses.
Three independent sets of gene signatures were used to fur-
ther characterize the tumors. Genes were matched across
datasets based on gene symbols, and matched genes were
centralized in our dataset across the 168 tumors. Nearest cen-
troid classifiers were used for the Sørlie and colleagues' [9]
and the Hu and colleagues' [10] subtype classifications, with
each tumor classified based on to which centroid it was most
correlated using Pearson correlation. The average expression
level for the genes in a signature was used to characterize
tumors for the Shipitsin and colleagues' gene signatures [5].
Hierarchical clustering was performed using MeV in the TM4
system [25] with complete linkage, Pearson correlation dis-
tance and gene centralization. Genes with different expression
levels in tumors containing CD44+/CD24- cells and tumors
lacking cells with this phenotype were identified using a two-
sided t test. To account for multiple comparisons, the false dis-
covery rate was calculated for gene lists. Sixty-nine of the 168
tumors with gene expression profiles were among the 240
tumors for which CD24 and CD44 immunohistochemical
stainings were obtained.
Results
Immunohistochemical expression of CD44 and CD24
We analyzed the presence of CD44 and CD24 antigens on
human breast cancer tissues using double-staining immuno-
histochemistry. The CD44 and CD24 expression was suc-
cessfully determined in 240 cases after excluding tumors with
scarce tissue on the TMA. These 240 tumors did not signifi-
cantly differ from the excluded 205 tumors in regard to tumor
size, lymph node status, S-phase fraction, ER status or dis-
ease-free survival. The median age was slightly higher in the
included patients (64 years versus 62 years for excluded
patients), although not reaching significance.
Figure 1 displays representative staining patterns of various
breast tumors. Tumor cells were distinguishable from stromal
cells and inflammatory cells (generally CD44+ and CD24-) by
expression of cytokeratin clone AE1/AE3 in adjacent sections.
The frequency of tumors with varying degrees of CD44+ and
CD24+ tumor cells is presented in Table 1. CD44 showed
mainly membranous staining (Permanent Red) with only six
tumors displaying cytoplasmic staining, four of which had also
membrane staining. Thirty-two percent (77/240) of the tumors
had ≥ 1% cells with membranous and/or cytoplasmic CD44
expression and were considered CD44+. CD24 was almost
exclusively detected in the cytoplasm, with only four tumors
displaying membrane DAB staining (all four with positive cyto-
plasmic staining as well). Forty-six percent (110/240) of the
tumors had ≥ 1% cells with CD24 staining and were consid-
ered CD24+.
To determine the proportion of putative tumorigenic CD44+/
CD24- cells within each tumor, we scanned for the presence
of Permanent Red staining without any DAB interference.
CD44+/CD24- tumor cells were detected in 31% (75/240) of
the tumors, with the proportion of this phenotype ranging from
only a few cells to almost all tumor cells (Figure 1a to 1c). The
frequency of tumors with different proportions of CD44+/
CD24- tumor cells is presented in Table 1. We also deter-
mined the proportion of CD44-/CD24+ and double-positive
(CD44+/CD24+) cells in each tumor (Table 1). CD44+/
CD24+ cells (Figure 1c) were detected in 6% (15/240) of the
tumors, while CD44-/CD24+  cells (Figures 1a, d) were
detected in 45% (108/240) of tumors. The majority of tumors
included at least a few double-negative (CD44-/CD24-) tumor
cells, while a complete lack of both proteins was evident in
35% (83/240). Thirteen percent (30/240) of the tumors were
positive for more than one of the CD44+/CD24-, CD44-/
CD24+ and CD44+/CD24+ phenotypes, with 5% (11/240)Breast Cancer Research    Vol 10 No 3    Honeth et al.
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displaying tumor cells of all three phenotypes. In 12% (28/
240) of the tumors, the majority (> 50%) of tumor cells was
CD44+/CD24-.
Correlation of CD44/CD24 status with tumor 
characteristics
HER2 expression was successfully determined in all 240
cases with CD44/CD24 data, and 16% (38/240) were con-
sidered strongly positive (score = 3). Information on other clin-
ical variables and patient survival was available from previous
studies. The CD44+/CD24- status was significantly correlated
to biological characteristics such as low/negative HER2
expression (P  = 0.002), elevated expression of CK5/14
(P = 0.012) and EGFR (P = 0.007) (Table 2). Interestingly, all
medullary tumors (n = 8) were positive for the CD44+/CD24-
phenotype. The presence of CD44+/CD24- tumor cells was
not associated with ER and PgR status, with S-phase fraction
or with tumor size, nor with lymph node status, menopausal
status or age, although showing a tendency of being more
common in premenopausal women. Using higher cutoff crite-
ria for the CD44+/CD24- status (10% or 50%) and comparing
these 50 tumors or 28 tumors, respectively, with all other
tumors gave more or less comparable results, although overall
slightly higher P values (data not shown). The only additional
significant association was with ER-negative status using a
10% cutoff value for the CD44+/CD24- status (P = 0.041).
Figure 1
Immunohistochemical double-staining of human breast tumors for CD44 and CD24 Immunohistochemical double-staining of human breast tumors for CD44 and CD24. CD44 is stained with Permanent Red and CD24 with diami-
nobenzidene (DAB). Magnification × 20. (a) A tumor positive for both CD44+/CD24- (white arrow) and CD44-/CD24+ (black arrow) cancer cells, 
although the predominant phenotype is CD44-/CD24-. (b) Almost all cells in this tumor are CD44+/CD24-. No CD24 staining is seen. (c) A tumor 
with predominantly CD44+/CD24- cells. A few CD44+/CD24+ cells are also present (black arrow). (d) A tumor positive for the CD44-/CD24+ phe-
notype. No CD44 staining is present.
Table 1
Scoring frequency of different CD44/CD24 phenotypes as determined by immunohistochemistry
Score CD44 (n = 240) CD24 (n = 240) CD44+/CD24- (n = 240) CD44-/CD24+ (n = 240) CD44+/CD24+ (n = 240)
0 (0%) 163 (68) 130 (54) 165 (69) 132 (55) 225 (94)
1 (1% to 10%) 26 (11) 73 (30) 25 (10) 72 (30) 14 (6)
2 (11% to 50%) 22 (9) 20 (8) 22 (9) 20 (8) 0 (0)
3 (51% to 75%) 15 (6) 10 (4) 15 (6) 10 (4) 0 (0)
4 (> 75%) 14 (6) 7 (3) 13 (5) 6 (3) 1 (0.4)
Data presented as n (%).Available online http://breast-cancer-research.com/content/10/3/R53
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Table 2
Association of CD44+/CD24- phenotype with clinical characteristics
Characteristic All tumors (n = 240) Negative (0%) (n = 165) Positive (> 0%) (n = 75) P valuea
Median age (years) 64.1 64.3 63.5 1.0
Menopausal status 0.098
Premenopausal 42 (18) 24 (15) 18 (24)
Postmenopausal 198 (83) 141 (85) 57 (76)
Tumor size 0.58
> 20 mm 183 (76) 143 (75) 40 (80)
≤ 20 mm 57 (24) 47 (25) 10 (20)
Lymph node status 0.19
Positive (n > 0) 159 (66) 114 (69) 45 (60)
Negative (n = 0) 81 (34) 51 (31) 30 (40)
S-phase fraction 1.0
High (> 12%) 37 (26) 29 (26) 8 (27)
Low (< 12%) 106 (74) 84 (74) 22 (73)
Missing 97
Histologic type < 0.001
Ductal 176 (77) 119 (77) 57 (78)
Lobular 28 (12) 23 (15) 5 (7)
Lobular + ductal 13 (6) 11 (7) 2 (3)
Medullary 8 (4) 0 (0) 8 (11)
Other 3 (1) 2 (1) 1 (1)
Missing 12
Estrogen receptor 0.45
Positive (> 25 fmol/mg) 159 (68) 112 (70) 47 (64)
Negative 74 (32) 48 (30) 26 (36)
Missing 7
Progesterone receptor 0.89
Positive (> 25 fmol/mg) 114 (49) 79 (49) 35 (48)
Negative 119 (51) 81 (51) 38 (52)
Missing 7
HER2 0.002
Strong (score = 3) 38 (16) 34 (21) 4 (5)
Weak/negative 202 (84) 131 (79) 71 (95)
Cytokeratin 5/14b 0.012
Strong 28 (13) 17 (10) 11 (25)
Weak/negative 188 (87) 155 (90) 33 (75)
Missing 24
Epidermal growth factor receptorc
Strong 27 (11) 12 (7) 15 (20)
Weak/negative 210 (89) 150 (93) 60 (80)
Missing 3
Distant metastasis 1.0
Positive 73 (30) 50 (30) 23 (31)
Negative 167 (70) 115 (70) 52 (69)
Data presented as n (%). aP values were calculated using Fisher's exact test, except for age where the Mann-Whitney U test was used. The 
missing categories were always excluded. bScoring as previously described [12]. cScoring as previously described [20].Breast Cancer Research    Vol 10 No 3    Honeth et al.
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The presence of CD44-/CD24+ tumor cells was solely associ-
ated with strong HER2 staining (P = 0.002) and not with any
other tumor characteristics. The presence of double-positive
(CD44+/CD24+, n = 15) tumor cells was not associated with
any tumor features, although an increase of tumors of medul-
lary type was indicated compared with tumors lacking cells
with this phenotype (23% versus 2%).
CD44+/CD24- status and survival
We did not see any correlation between CD44+/CD24- status
and distant disease-free survival, nor between CD44+/CD24-
status and site of distant recurrence. Factors significantly cor-
related to favorable distant disease-free survival at 5-year fol-
low-up (in this cohort of patients receiving adjuvant tamoxifen
therapy) included positive ER and PgR status (P = 0.005 and
P = 0.037, respectively) and negative CK5/14 and EGFR sta-
tus (P = 0.035 and P = 0.005, respectively), but not HER2
and lymph node status, while tumor size and a high S-phase
fraction reached marginal significance. Lymph node status,
however, was correlated to distant disease-free survival in the
entire cohort of 445 tumors (P = 0.005).
Definition of breast cancer subgroups by tumor markers 
and correlation with gene expression subtypes
The CD44+/CD24- phenotype was clearly related to certain
tumor biological characteristics. To study this relation in more
depth, we used five protein markers available for 232 out of
the 240 cases with CD44/CD24 data to define five tumor sub-
groups. Tumors positive for ER and/or PgR were designated
steroid receptor positive (SR+). The SR and HER2 status was
used to broadly divide tumors into four subgroups; SR+HER2-
(n = 150), SR+HER2+ (n = 14), SR-HER2+ (n = 24), and
SR-HER2- (triple negative, n = 44). The latter group was fur-
ther subdivided into a subgroup expressing basal CK5/14
and/or EGFR (SR-HER2- basal-like, n = 30), and a subgroup
negative for all five markers (SR-HER2- nonbasal, n = 14).
Gene expression data were available for 69 of the 232 tumors,
which allowed us to correlate our five subgroups, as defined
by the five tumor markers, with breast cancer subtypes defined
by gene expression profiling and intrinsic gene lists [9,10]. As
seen in Figure 2, SR+HER2- tumors were clearly enriched for
luminal A tumors, while SR-HER2- basal-like tumors corre-
sponded prominently to the basal-like subtype defined by
gene expression profiling. As expected, SR-HER2+ tumors
correlated well with the HER2+ subtype. The SR-HER2- non-
basal subgroup showed no clear association with any tumor
subtype – and only two tumors were SR+HER2+, making it
difficult to draw any conclusions for this subgroup. We there-
fore conclude that tumor classification based on a combina-
tion of five commonly used tumor protein markers is
biologically relevant for subgroup analysis in our tumor
material.
CD44/CD24 status in different breast cancer subgroups
The expression of CD44 and CD24 differed significantly
between the subgroups (P = 0.001 and P = 0.035, respec-
tively) (Table 3). CD44 was highly expressed in the SR-HER2-
basal-like subgroup, with 63% of the tumors being positive
compared with 32% for the entire cohort, and was very lowly
Figure 2
Hierarchical clustering of 69 tumor samples with available gene expression data Hierarchical clustering of 69 tumor samples with available gene expression data. Clustering was based on 364 genes from the intrinsic gene list 
published by Sørlie and colleagues [9] that matched our cDNA clones. Colored boxes indicate classification of each tumor into subtypes/sub-
groups. Filled or open boxes indicate the percentage of cells in each tumor positive for the CD44+/CD24- and CD44-/CD24+ phenotypes as deter-
mined by immunohistochemistry. SR, steroid receptor. Hu classification, Hu and colleagues [10].Available online http://breast-cancer-research.com/content/10/3/R53
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expressed in the HER2+ groups, with only 14% and 17% of
the tumors being positive in the SR+HER2+ and SR-HER2+
groups, respectively. CD24 was highly expressed in the SR-
HER2+ group (75% compared with 47% for the entire
cohort).
The frequency of tumors positive for the CD44+/CD24- pheno-
type varied significantly between the different subgroups (P <
0.001, Table 3). While close to two-thirds (63%) of tumors
resembling the basal-like subtype (SR-HER2- basal-like)
expressed CD44+/CD24- cells, this phenotype was very low in
HER2+ tumors, regardless of SR status: 8% in SR-HER2+
tumors and 14% in SR+HER2+ tumors (Table 3). The diver-
gence between subgroups remained when the cutoff level for
CD44+/CD24- was raised to 10% or 50% (P = 0.003 and P
= 0.033, respectively). The frequency of CD44+/CD24- cells
within tumors positive for this phenotype was also higher in
basal-like tumors, as indicated in Figure 2 for the 69 tumors
with gene expression data.
The proportion of tumors with CD44-/CD24+ cells also dif-
fered significantly between subgroups (P = 0.027), with the
highest proportion in the two HER2+ groups (SR-HER2+ and
SR+HER2+) (Table 3). The presence of double-positive
(CD44+/CD24+) and double-negative (CD44-/CD24-) tumor
cells did not differ between subgroups (Table 3).
CD44+/CD24- status in BRCA1-defective tumors
Since there was a clear correlation between the CD44+/
CD24- status and the basal-like tumor subtype, we extended
the immunohistochemical analysis to an additional TMA
including tumors from BRCA1 hereditary breast cancer
patients, known to be of predominantly basal-like phenotype
[9]. A basal-like status was verified for nine of our BRCA1
hereditary tumors for which gene expression data were
available.
Seventeen of the 23 BRCA1-defective tumors were success-
fully stained for CD44 and CD24 expression. The frequency of
Table 3
Association of CD44/CD24 phenotypes with breast cancer subgroups
Phenotype All tumors
(n = 232)
SR+HER2-
(n = 150)
SR+HER2+
(n = 14)
SR-HER2+
(n = 24)
SR-HER2- P valuea
Basal-like
(n = 30)
Nonbasal
(n = 14)
CD44 0.001
Positive
(> 0%)
75 (32) 47 (31) 2 (14) 4 (17) 19 (63) 3 (21)
Negative 157 (68) 103 (69) 12 (86) 20 (83) 11 (37) 11 (78)
CD24 0.035
Positive
(> 0%)
108 (47) 65 (43) 8 (57) 18 (75) 12 (40) 5 (36)
Negative 124 (53) 85 (57) 6 (43) 6 (25) 18 (60) 9 (64)
CD44+/CD24- < 0.001
Positive
(> 0%)
73 (31) 47 (31) 2 (14) 2 (8) 19 (63) 3 (21)
Negative 159 (69) 103 (69) 12 (86) 22 (92) 11 (37) 11 (79)
CD44-/CD24+ 0.027
Positive
(> 0%)
106 (46) 63 (42) 8 (57) 18 (75) 12 (40) 5 (36)
Negative 126 (54) 87 (58) 6 (43) 6 (25) 18 (60) 9 (64)
CD44+/CD24+ 0.61
Positive
(> 0%)
14 (6) 9 (6) 0 (0) 3 (12) 2 (7) 0 (0)
Negative 218 (94) 141 (94) 14 (100) 21 (88) 28 (93) 14 (100)
CD44-/CD24- 0.28
100% 78 (28) 57 (31) 4 (24) 5 (18) 6 (18) 6 (40)
< 100% 197 (72) 125 (69) 13 (76) 23 (82) 27 (82) 9 (60)
Data presented as n (%). SR, steroid receptor. aP values were calculated using Fisher's exact test.Breast Cancer Research    Vol 10 No 3    Honeth et al.
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tumors with different proportions of CD44+/CD24- cells is pre-
sented in Table 4. Ninety-four percent (16/17) of the tumors
were positive for this phenotype, thus corroborating the find-
ing of a high proportion of CD44+/CD24- cells in the SR-
HER2- basal-like subgroup (Table 4). BRCA1 germline mutant
tumors, however, also had a high proportion (70%) of cells
positive for the CD44-/CD24+ phenotype, considerably higher
than the 40% seen among SR-HER2- basal-like tumors.
Correlation to published prognostic gene signatures
We correlated the presence of CD44+/CD24- cells to two
gene signatures with prognostic value specific for either
CD44+ or CD24+ breast cancer cells published by Shipitsin
and colleagues [5]. Signatures A and B are associated with
shorter and longer distant recurrence-free survival time,
respectively. A positive correlation of CD44+/CD24- cells to
signature A was seen if the cutoff level for CD44+/CD24- was
50% or 75% positive cells (P = 0.05 and P = 0.008, respec-
tively) but not when using lower cutoff levels. A negative
correlation to signature B was seen when using cutoff levels
of 0%, 10% or 75% positive cells (P < 0.001, P < 0.001 and
P = 0.01, respectively).
Gene expression signature of the CD44+/CD24- 
phenotype
To identify a gene expression signature for the CD44+/CD24-
phenotype, we used the 69 tumors with gene expression data
and looked for genes differentially expressed between tumors
containing CD44+/CD24- cells and tumors lacking such cells.
The top 20 genes are displayed in Table 5. Interestingly, CD44
emerged as the second ranked gene, demonstrating a good
correspondence between protein and mRNA levels for this
gene – although the top 20 genes collectively had a relatively
high false discovery rate of 28%.
Discussion
The concept of cancer stem cells relies on the presence of a
subpopulation of cells within tumors that drives tumorigenesis,
as well as giving rise to a large population of differentiated
progeny that constitute the bulk of the tumor but lack tumori-
genic potential [26]. Multiple studies indicate that CD44+/
CD24- breast cancer cells have tumor-initiating properties [1-
3].
In the present study, we have explored the dual expression of
CD44 and CD24 in a sample of 240 stage II breast tumors
with specific regard to breast cancer subtypes. The CD44
staining was almost exclusively membranous, which is con-
cordant with prior literature [27], while CD24 predominantly
stained the cytoplasm. Earlier publications have shown either
membranous and/or cytoplasmic CD24 staining [28,29]. Bir-
can and colleagues observed a cytoplasmic CD24 staining
pattern in neoplastic breast tissue while it was mainly detected
in the cell membrane in normal breast [30]. Intracytoplasmic
CD24 expression has been suggested to reflect overexpres-
sion of the protein or disturbance of the protein distribution or
degradation in neoplastic cells [31]. It is reasonable to sus-
pect that cells with a cytoplasmic CD24 pattern also express
CD24 protein on the cell surface. The specificity of the CD24
antibody has earlier been ascertained by flow cytometric anal-
ysis [32].
Overall, we saw a large heterogeneity of CD44 and CD24
expression between tumors, but also within tumors where the
proportion of positive cells varied considerably. Interestingly,
tumor cells were mostly positive for either CD44 or CD24 and
rather few tumors contained double-positive cells, although it
was quite common that individual tumors contained both
CD44+ and CD24+ cells. A recent study by Shipitsin and cow-
orkers implicated that CD24+ and CD44+ cells within breast
carcinomas represent defined cell populations with distinct
genetic profiles [5]. They showed that CD24+ cells were more
differentiated while CD44+ cells had more progenitor-like fea-
tures, suggesting that CD24+ cells might be derived from
CD44+  cells. Findings from our study could support this
hypothesis, in that the variable presence of tumor cells that are
largely either CD44+ or CD24+ may reflect the current state of
a tumor undergoing constant cell renewal, differentiation and
death at a pace defined by their intrinsic machinery and inter-
action with surrounding stroma.
Contradictive to results by Al-Hajj and colleagues demonstrat-
ing CD44+/CD24- cells in all their breast cancer samples [1],
we only detected cells with this phenotype in 31% of our
tumors. This discordance could depend on their study involv-
ing mainly metastatic tissues, including only one primary
tumor. Metastatic tumor cells may have a more stem cell-like
Table 4
Scoring frequency of CD44+/CD24- cells in BRCA1-defective breast tumors in comparison with SR-HER2- basal-like tumors
Score SR-HER2- basal-like (n = 30) BRCA1 mutant (n = 17)
0 (0%) 11 (37) 1 (6)
1 (1% to 10%) 4 (13) 4 (24)
2 (11% to 50%) 6 (20) 6 (35)
3 (51% to 75%) 4 (13) 1 (6)
4 (> 75%) 5 (17) 5 (29)
Data presented as n (%). SR, steroid receptor.Available online http://breast-cancer-research.com/content/10/3/R53
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phenotype, as indicated by enrichment of the CD44+/CD24-
phenotype in bone marrow micrometastasis of breast cancer
patients [33]. A recent study demonstrated CD44+/CD24-
cells in 59% of human breast tumors, further supporting that
not all breast tumors contain cells with this phenotype [34].
We found that the CD44+/CD24- status was associated with
low/negative HER2 expression and with elevated expression
of CK5/14 and EGFR, as well as with medullary histological
type, all known characteristics of the basal-like subtype of
breast cancer. This motivated further analysis of the preva-
lence of CD44+/CD24- cells in different tumor subtypes.
Since previous studies have demonstrated a good resem-
blance of subgroups defined by common tumor markers to
molecular subtypes defined by mRNA expression patterns
[13,14], we used cytosolic protein levels of ER and PgR and
used TMA immunostaining of HER2, CK5/14 and EGFR to
classify the material into five tumor subgroups. Using available
gene expression data for 69 of the tumors and using published
intrinsic gene lists [9,10], we could demonstrate a reasonable
correlation to molecular subtypes for three of our five sub-
groups, justifying a subgroup analysis of CD44+/CD24-
expression. We could thereby demonstrate an association
between the presence of CD44+/CD24- tumor cells and a
basal-like subgroup of breast cancer. This finding is consistent
with a recent publication where Sheridan and colleagues
observed a correlation between breast cancer cell lines with a
basal/myoepithelial origin and CD44+/CD24- expression [3].
Moreover, we observed that basal-like tumors often had a
higher proportion of CD44+/CD24- cells, while tumors of other
subtypes that contained CD44+/CD24- cells generally had a
lower number of cells with this phenotype. This observation
corroborates prior work indicating that basal-like tumors have
a greater stem cell-like phenotype [35]. These tumors may
originate from the most primitive ER-negative stem/progenitor
cells, suggesting a block in differentiation upstream of ER-pos-
itive progenitor cells [36]. Tumors developing in BRCA1
germline mutation carriers are typically of basal-like subtype,
possibly due to the critical role BRCA1 plays in the differenti-
ation of ER-negative stem/progenitor cells to ER-positive lumi-
nal cells [37]. Accordingly, we found that all but one of the 17
BRCA1 tumors contained CD44+/CD24- cells, further illus-
Table 5
Top 20 genes differing between tumor with and without the presence of CD44+/CD24- tumor cells
Rank Clonea Gene descriptionb Gene symbol Signc
1 1499830 Myocardial infarction associated transcript (nonprotein coding) MIAT -
2 82421 CD44 molecule (Indian blood group) CD44 +
3 2018758 Peroxisomal biogenesis factor 7 PEX7 +
4 320712 Protein kinase, X-linked, pseudogene 1 PRKXP1 -
5 824908 Transmembrane protein 49 TMEM49 -
6 328868 CD44 molecule (Indian blood group) CD44 +
7 1472689 Apolipoprotein C-I APOC1 -
8 126341 Myosin, light chain kinase MYLK +
9 1609752 Apolipoprotein C-I APOC1 -
10 811028 Transmembrane protein 49 TMEM49 -
11 788714 Ataxin 10 ATXN10 +
12 310019 Myosin, light chain kinase MYLK +
13 137296 SEC24 related gene family, member A (S. cerevisiae) SEC24A -
14 32493 Integrin, α6 ITGA6 +
15 754582 Ecotropic viral integration site 2A EVI2A -
16 1159963 Interferon regulatory factor 7 IRF7 -
17 612576 3-Oxoacid CoA transferase 1 OXCT1 +
18 503724 Transcribed locus, strongly similar to NP_034722.1 jun D proto-oncogene (Mus musculus) Unavailable data +
19 810463 Dehydrogenase/reductase (SDR family) member 7B DHRS7B -
20 502067 Lupus brain antigen 1 LBA1 -
aIntegrated Molecular Analysis of Genomes and their Expression (IMAGE) consortium cDNA clone number. bClones mapped using UniGene 
Build 208 (National Center for Biotechnology Information, Bethesda, Maryland, USA). cGenes are either upregulated (+) or downregulated (-) in 
tumors containing CD44+/CD24- tumor cells.Breast Cancer Research    Vol 10 No 3    Honeth et al.
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trating the correlation between CD44+ status and basal-like/
BRCA1-like tumors.
Interestingly, the HER2+ tumor subtype, generally considered
an aggressive form of breast cancer, displayed a low fre-
quency of tumors containing CD44+/CD24- cells and was in
fact often positive for the CD44-/CD24+ phenotype. CD24
expression has been shown to contribute to the more differen-
tiated state of committed cells [38], but has also been associ-
ated with rapid cell spreading, increased cell motility and
invasion [39]. In normal breast epithelium, basal/myoepithelial
cells but not luminal epithelial cells express CD44 [27] while
CD24 is highly expressed in luminal cells [40]. The predomi-
nantly CD24+ phenotype of HER2+ tumors may reflect the ori-
gin for at least some of these tumors from a CD24+ luminal
epithelial cell type [40].
We did not see any association between the CD44+/CD24-
status and markers known to be important for the clinical out-
come, including tumor size, nodal status or S-phase fraction.
These results are partly in accordance with previous observa-
tions by Abraham and colleagues [6], although these authors
reported that tumors with a higher fraction of CD44+/CD24-
cells were more commonly found in patients diagnosed with
distant metastases. We saw no such trend in our material,
regardless of whether analyzing the whole material or different
subgroups separately.
Since all patients in our study received adjuvant tamoxifen
therapy the lack of correlation to survival should however be
cautiously interpreted. We therefore evaluated prognostic
gene signatures specific for either CD44+ cells (signature A)
or CD24+ cells (signature B) published by Shipitsin and col-
leagues [5], shown to be associated with short and long dis-
tant recurrence-free survival, respectively, in patients not
undergoing adjuvant systemic therapy. Interestingly, we saw a
significant positive correlation of tumors with a high (> 50%)
proportion of CD44+/CD24- cells to signature A, and a signif-
icant negative correlation between the presence of CD44+/
CD24- cells and signature B. This observation indicates that a
high proportion of CD44+/CD24- cells could therefore be a
marker of aggressive phenotype also in our material, although
we saw no correlation with prognosis.
We detected a gene expression signal for tumors containing
CD44+/CD24- cells. Although the false discovery rate was
high, the signature is strengthened by the fact that CD44
occurs as the top second gene. Interestingly, α6-integrin also
appears as one of the top overexpressed genes. This gene
(also known as CD49f) has previously been used to identify
mammary epithelial stem cells [41] and was recently demon-
strated to be necessary for tumorigenicity of MCF7 breast
cancer cells [42].
Conclusion
Our results demonstrate a clear variation in the prevalence of
CD44+/CD24- tumor cells between breast tumors of different
subtypes. The occurrence of this phenotype is high in basal-
like tumors – and especially in BRCA1 hereditary tumors – is
lower in tumors of luminal type and is particularly low in the
HER2+ tumors, irrespective of ER status. These results
emphasize the biological heterogeneity of breast cancer and
an enrichment of putative tumor-initiating cells in the aggres-
sive basal-like tumor subtype. Far from all basal-like tumors
contain CD44+/CD24- cells, however, and their scarcity in
HER2+ tumors suggests that tumorigenicity may not be con-
fined to cells of this phenotype and that other markers remain
to be identified. Moreover, the obvious heterogeneity of cells
with various CD44/CD24 expression within individual tumors
may be indicative of a cancer stem cell subpopulation giving
rise to more differentiated and committed cell populations.
This does by no means exclude the coexistence of cancer cell
clones of independent origin, evolution and tumorigenic ability.
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